Heart failure after myocardial infarction
Conditions
Interventions
Vericiguat Treatment Group:None
Standard Care Group:None
Sponsors
Beijing Friendship Hospital ,Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with heart failure following acute myocardial infarction. 2.Age =18 years. 3.Voluntary acceptance of the study protocol and follow-up assessments, with signed written informed consent.
Exclusion criteria
Exclusion criteria: 1.History of previous myocardial infarction. 2.Significant hematological abnormalities; active bleeding or significant bleeding tendency, including active ulcers, recent ischemic stroke, history of hemorrhagic stroke, intracranial space-occupying lesions, recent craniocerebral trauma, other active organ bleeding or bleeding tendency that is difficult to control. 3.Patients who have undergone cardiac valve surgery within the past 3 months or coronary artery bypass grafting within the past 60 days. 4.Concurrent use or anticipated use of long-acting nitrates, soluble guanylate cyclase (sGC) stimulators, or phosphodiesterase-5 (PDE5) inhibitors. These medications may interact with the study drug or affect study outcomes. 5.Coexisting cardiovascular diseases with known etiology, including: history of severe valvular stenosis or regurgitation; other cardiomyopathies with known causes such as alcoholic cardiomyopathy, stress-induced cardiomyopathy, peripartum cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy; history of congenital heart disease; acute myocarditis or acute myopericarditis. 6.Patients with implanted left ventricular assist devices or awaiting heart transplantation. 7.Patients with severe diseases with life expectancy less than 12 months, such as malignant tumors or other end-stage diseases. 8.Pregnant or lactating women. 9.Patients in the vericiguat group who did not receive treatment according to standard therapeutic strategy. 10.Other conditions deemed unsuitable for this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CMR Assessment of Changes in Myocardial Infarct Size to Left Ventricular Mass Ratio at 3 Months in Patients with Heart Failure after Myocardial Infarction.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cardiac Magnetic Resonance Assessment of Microvascular Obstruction, Intramyocardial Hemorrhage, Microvascular Dysfunction, Infarct Size, Area of Myocardial Edema, and Myocardial Salvage Index Within t;MACE: Including All-cause Death, Cardiac Death, Recurrent Myocardial Infarction, Repeat Coronary Revascularization, Stent Thrombosis, Stroke, Rehospitalization for Angina and Heart Failure;Changes in cardiac parameters including LVEF, LVEDVI, LVESVI, LVMI, CI, LV remodeling index, infarct size changes, viable myocardium area, and strain parameters of cardiac.;Adverse Events: Including Abnormal Liver Function, Abnormal Kidney Function, and Intermittent Symptoms During Treatment (Including Allergies, Cardiac Arrhythmia, and GI Reactions.; | — |
Countries
China
Contacts
Public ContactRongchong Huang
Beijing Friendship Hospital ,Capital Medical University
Outcome results
None listed